알피바이오

314140KOSDAQ의약품 제조업

67.8 / 100

Reference Date: 2026-07-24

Financial Score25.5 / 40

News Sentiment21.3 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly up 2.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Alpibio produces and sells pharmaceuticals (cold medicine, pain relievers) and health functional foods (omega-3, diet supplements) in various forms, including soft capsules, through OEM/ODM models. It holds over 60% of the domestic pharmaceutical soft capsule market and is rapidly growing its health functional food sales, driven by market expansion and R&D efforts with numerous patents.

Number of Employees

534people

Average Salary

37.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

9.98Industry Average 11.235.0Point

In line with industry avg

PBR

0.44Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

4.47Industry Average 4.014.0Point

In line with industry avg

Debt Ratio

4.34Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲361.4% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.1% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
"생리통·붓기·장 불편까지"?알피바이오, 여성용 복합 진통제 개발
알피바이오의 새로운 여성용 복합 진통제 개발로 인해 시장에서 긍정적인 반응을 얻고 있다.
Positive
" 생리통·설사 한 번에 잡는다" 알피바이오, '3세대 여성 진통제'...
알피바이오의 새로운 '3세대 여성 진통제' 개발로 여성 생리통 관련 시장에서의 혁신적 성과를 보여주며 긍정적인 투자 전망을 제공합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 5,400Won52-week high 8,01052-week low 5,060

1-month return4.0Point

1m +2.47% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral대표이사변경2026-06-30